HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: 291/5/F932    most recent 00200.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Jie, K. E. Articles by Braam, B. Search for Related Content PubMed PubMed Citation Articles by Jie, K. E. Articles by Braam, B.

INVITED REVIEW

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors

Departments of ¹Nephrology and Hypertension, ²Vascular Medicine, and ³Cardiology, University Medical Center Utrecht, Utrecht; and ⁴Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands

Submitted 5 June 2006 ; accepted in final form 12 July 2006

We have recently proposed severe cardiorenal syndrome (SCRS), in which cardiac and renal failure mutually amplify progressive failure of both organs. This frequent pathophysiological condition has an extremely poor prognosis. Interactions between inflammation, the renin-angiotensin system, the balance between the nitric oxide and reactive oxygen species and the sympathetic nervous system form the cardiorenal connectors and are cornerstones in the pathophysiology of SCRS. An absolute deficit of erythropoietin (Epo) and decreased sensitivity to Epo in this syndrome both contribute to the development of anemia, which is more pronounced than renal anemia in the absence of heart failure. Besides expression on erythroid progenitor cells, Epo receptors are present in the heart, kidney, and vascular system, in which activation results in antiapoptosis, proliferation, and possibly antioxidation and anti-inflammation. Interestingly, Epo can improve cardiac and renal function. We have therefore reviewed the literature with respect to Epo and the cardiorenal connectors. Indeed, there are indications that Epo can diminish inflammation, reduce renin-angiotensin system activity, and shift the nitric oxide and reactive oxygen species balance toward nitric oxide. Information about Epo and the sympathetic nervous system is scarce. This analysis underscores the relevance of a further understanding of clinical and cellular mechanisms underlying protective effects of Epo, because this will support better treatment of SCRS.

heart failure; renal failure; anemia; nitric oxide; reactive oxygen species

This article has been cited by other articles:

				D. Mihov, J. Vogel, M. Gassmann, and A. Bogdanova Erythropoietin activates nitric oxide synthase in murine erythrocytes Am J Physiol Cell Physiol, August 1, 2009; 297(2): C378 - C388. [Abstract] [Full Text] [PDF]

				A. Kazory and E. A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647. [Abstract] [Full Text] [PDF]

				S. S. Billecke, L. G. D'Alecy, R. Platel, S. E. Whitesall, K. A. Jamerson, R. L. Perlman, and C. A. Gadegbeku Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease Nephrol. Dial. Transplant., February 1, 2009; 24(2): 489 - 496. [Abstract] [Full Text] [PDF]

				C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo Cardiorenal Syndrome J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1527 - 1539. [Abstract] [Full Text] [PDF]

				J. P. Pinto, S. Ribeiro, H. Pontes, S. Thowfeequ, D. Tosh, F. Carvalho, and G. Porto Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBP{alpha} Blood, June 15, 2008; 111(12): 5727 - 5733. [Abstract] [Full Text] [PDF]